SNGX Stock Analysis: Buy, Sell, or Hold?
SNGX - Soligenix, Inc. Common Stock
$0.29
-0.02 (-4.93%)
▼
5d:
-15.07%
30d:
-74.3%
90d:
-74.07%
WAIT
LOW Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 08, 2026
0d
Get Alerted When SNGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called SNGX this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SNGX is down 15.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SNGX is down 15.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SNGX is currently trading at $0.29, which is considered oversold relative to its 30-day fair value range of $0.65 to $1.39.
Technical Outlook: Technically, SNGX is in a downtrend. The price is currently testing key support at $0.29. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+4767.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNGX is in a downtrend. The price is currently testing key support at $0.29. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+4767.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.65 -
$1.39
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 4767.0% below Wall St target ($15.00)
- WARNING: Recommendation downgraded due to -15.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.65 -
$1.39
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.30
Resistance Level
$1.43
Current Trend
Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.23
Wall Street Target
$15.00
(+4767.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 08, 2026 4:13 PM ET
Data refreshes hourly during market hours. Next update: 5:13 PM
Data refreshes hourly during market hours. Next update: 5:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 46 HOLD |
